Table 4. Predicted Drug-Likeness and ADMET Properties for Compounds 8b, 8c, and Standard Drugs Fluconazole (FLC), Ravuconazole (RAV), and Itraconazole (ITR).

cmpd	drug-likenessa	HIAb	bioavailability scorecC	PPBd	hERG inhibitione	CYP3A4 substratee	carcinogenicitye	water solubilitycC
8b	yes	91.8	0.55	98.9	medium risk	weakly	negative	moderately soluble
8c	yes	92.95	0.55	99.9	medium risk	substrate	negative	moderately soluble
FLC	yes	95.7	0.55	55.15	medium risk	substrate	negative	soluble
RAV	yes	95.58	0.55	91.44	medium risk	substrate	negative	moderately soluble
ITR	no	96.6	0.17	95.3	medium risk	substrate	negative	poorly soluble

^aLipinski’s rule of 5: MW < 500 Dalton, Log P < 5, hydrogen-bond donors < 5, hydrogen-bond acceptors < 10, rotatable bonds < 10.

^bHuman intestinal absorption (%), calculated by PreADMET.

^cCalculated by SwissADME.

^dPlasma protein binding, calculated by PreADMET.

^eCalculated by PreADMET.